Rapid Micro Rejects Takeover Deal, Adopts Poison Pill To Thwart Investor
Rapid Micro Biosystems Inc (NASDAQ: RPID) has initiated a review of strategic alternatives and has retained Morgan Stanley & Co. LLC as…
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
The Phase 2b clinical study was designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.
Daiichi-AstraZeneca’s Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
The FDA has approved Daiichi Sankyo (OTC:DSNKY) and AstraZeneca plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC)…
Aptinyx’s Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study
Aptinyx Inc (NASDAQ: APTX) has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness and localized tenderness at specific points.
Novavax Nuvaxovid COVID-19 Vaccine Approved In South Korea For Use In Adolescents Aged 12 Through 17
GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced
UNITY Biotech Shares More Than Double On Positive Drug Data For Diabetes Associated Vision Loss
UNITY Biotechnology Inc (NASDAQ:UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for…
Johnson & Johnson To Stop Selling Talc-Based Powder
Johnson & Johnson (NYSE:JNJ) said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move amid…
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder
Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD).
Pfizer Announces Top-Line Results From Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine In Infants; Says 20vPnC Demonstrated Favorable Safety And Tolerability Profile
Pivotal top-line data demonstrate a four-dose series of 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…